Review Article

The Molecular Basis and Therapeutic Potential of *Let-7* MicroRNAs against Colorectal Cancer

Rei Mizuno, Kenji Kawada , and Yoshiharu Sakai

Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Correspondence should be addressed to Kenji Kawada; kkawada@kuhp.kyoto-u.ac.jp

Received 22 March 2018; Accepted 6 June 2018; Published 19 June 2018

Academic Editor: Maikel P. Peppelenbosch

Copyright © 2018 Rei Mizuno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Although a number of studies have revealed the underlying mechanisms which regulate the development of colorectal cancer (CRC), we have not completely overcome this disease yet. Accumulating evidence has shown that the posttranscriptional regulation by the noncoding RNAs such as microRNAs plays an important role in the development or progression of CRC. Among a number of microRNAs, the *let-7* microRNA family that was first discovered in *C. elegans* and conserved from worms to humans has been linked with the development of many types of cancers including CRC. The expression level of *let-7* microRNAs is temporally low during the normal developmental processes, while elevated in the differentiated tissues. The *let-7* microRNAs regulate the cell proliferation, cell cycle, apoptosis, metabolism, and stemness. In CRC, expressions of *let-7* microRNAs have been reported to be reduced, and so *let-7* microRNAs are considered to be a tumor suppressor. In this review, we discuss the mechanisms regulating the *let-7* microRNA expression and the downstream targets of *let-7* in the context of intestinal tumorigenesis. The application of *let-7* mimics is also highlighted as a novel therapeutic agent.

1. Introduction

Colorectal cancer (CRC) is one of the most common causes of cancer deaths worldwide [1–3], and the number of CRC patients is increasing more and more [4]. Many studies have revealed the molecular mechanisms of the colonic tumorigenesis and have proposed various models such as the adenoma-carcinoma sequence (i.e., multistep carcinogenesis) and colitis-associated carcinogenesis observed in inflammatory bowel diseases (IBD). However, we have not yet completely understood the molecular basis of CRC tumorigenesis. One of the reasons which makes our understanding difficult is that not only genetic changes, such as mutation/deletion of oncogenes or tumor suppressor genes, but also the epigenetic modification or posttranscriptional regulation by RNA binding proteins and microRNAs is involved in the colonic tumorigenesis.

The *let-7* microRNAs are noncoding RNAs which consist of ~22 nucleotides [5]. They are first discovered in *C. elegans* as a critical regulator of developmental process [6, 7]. *Let-7* microRNAs have been experimentally confirmed to be conserved in a wide range of species including humans [8]. As the

let-7 family, 9 members are identified so far: *let-7a*, *let-7b*, *let-7c*, *let-7d*, *let-7e*, *let-7f*, *let-7g*, *let-7i*, and *miR-98*. The mature *let-7* negatively regulates the expression of target mRNAs at a posttranslational level via imperfect base pairing to the 3'-UTR of their target mRNAs [9]. During normal developmental process, the expression levels of *let-7* microRNAs in stem and progenitor cells are maintained low. As progenitor cells differentiate, *let-7* expression is increasing [10].

Let-7 microRNAs are downregulated in various types of cancers such as hepatocellular carcinoma (HCC), gastric adenocarcinoma, pancreatic cancer, ovarian cancer, prostate cancer, Burkitt lymphoma, renal cell carcinoma, breast cancer, and melanoma [11]. In the context of CRC, *let-7* microRNAs are also downregulated, which affects the posttranscriptional regulation of target mRNAs resulting in the colonic tumorigenesis and progression.

In this review, we discuss the molecular mechanisms by which *let-7* microRNAs regulate the colonic tumorigenesis, tumor progression, and chemotherapy resistance by a posttranscriptional regulation and also highlight the possibility of the application of *let-7* targeting therapy against CRC.

FIGURE 1: A schematic diagram of the *let-7* biogenesis. Pri-*let-7* microRNA precursors are processed in the nucleus by Drosha to pre-*let-7*. Pre-*let-7* microRNA precursors are exported to the cytoplasm by exportin-5, where they are subsequently processed by Dicer resulting in the mature *let-7*. RNA binding protein LIN28A or LIN28B binds to either pri-*let-7* or pre-*let-7* using RNA binding domains, cold shock domain (CSD), and two zinc finger domains (ZFDs) and blocks the processing. Upon binding to pre-*let-7*, LIN28A or LIN28B recruits TUTase, which causes oligouridylation resulting in the degradation of pre-*let-7*.

2. Biogenesis of *Let-7* MicroRNAs (Figure 1)

Mature *let-7* microRNAs are synthesized through the multiple processing by microprocessors [12]. *Let-7* microRNAs are initially transcribed in long transcripts called primary *let-7* (pri-*let-7*), which are processed in the nucleus by Drosha and Pasha to pre-*let-7* with hairpin structures of about 70 nucleotides. Next, pre-*let-7* are exported to the cytoplasm by exportin-5, where they are subsequently processed by the enzyme Dicer resulting in the mature *let-7* [12]. *Let-7* is known to be negatively regulated by the RNA binding proteins, LIN28A or LIN28B. LIN28A or LIN28B has two RNA binding domains, cold shock domain (CSD) and two Cys-Cys-His-Cys- (CCHC-) type zinc finger domains (ZFDs) [13–16], which bind to the conserved GGAG motif in the terminal loop of pri-*let-7* or pre-*let-7*, respectively, resulting in the inhibition of the maturation of *let-7* [17, 18]. The binding of LIN28A or LIN28B to either pri-*let-7* or pre-*let-7* inhibits the processing of *let-7* precursors by Drosha and Dicer [19]. Upon binding to pre-*let-7*, LIN28A or LIN28B recruits TUT4/TUT7, which causes oligouridylation at the 3' terminal of pre-*let-7* [20–22]. Under normal conditions, Dicer recognizes the two nucleotides at the 3' terminal via its PAZ domain; however, oligouridylation elongates the 3' terminal resulting in the resistance to Dicer cleavage. Oligouridylated pre-*let-7* can also be degenerated by the 3'-5' exonuclease Dis312 [23, 24]. Thus, LIN28A or LIN28B not only inhibits the biogenesis of *let-7* family miRNAs, but also induces their degradation. LIN28A and LIN28B are the negative regulators of *let-7* microRNAs, and so the expression level of LIN28A is high in the developmental process, while that of LIN28B is low in the adult tissues [10]. LIN28B has two isoforms: LIN28B-long and LIN28B-short isoforms. Both

isoforms preserve the binding ability to pre-*let-7*. However, LIN28B-short isoform lacks the inhibitory ability against the processing by microprocessors. Namely, LIN28B-short isoform functions as a competitor against the LIN28B-long isoform in the context of *let-7* maturation [25].

3. *Let-7* and Colon Cancer

Regarding the LIN28AB/*let-7* axis, the downregulation of *let-7* or upregulation of either LIN28A or LIN28B has been reported to be related to the worse prognosis in CRC patients. Stage I/II CRC patients with high expression of LIN28B exhibit poorer prognosis compared to those with no LIN28B expression [26]. King et al. reported that the expression level of LIN28B was inversely correlated to that of mature *let-7a* in human CRC [27]. Tu et al. examined the expression of LIN28A or LIN28B in the cohort of almost 600 CRC patients and found that LIN28A or LIN28B was highly expressed in 38 % of CRC patients [28]. Importantly, the overall survival was lower in the patients with high expression of LIN28A or LIN28B than in those with low expression of LIN28A or LIN28B. Madison et al. demonstrated that intestinal tumors were spontaneously developed in the transgenic mice with intestinal-specific LIN28B expression (*Villin-Lin28b*), which suggests that LIN28B functions as an oncogene [29]. *Let-7b* and *let-7c* can escape the downregulation by LIN28B in mice. Therefore, they crossed these mice with *let-7b* and *let-7c* knockout mice (*let-7^{IEC-KO}*) and found that the additional downregulation of *let-7b* and *let-7c* resulted in the increase of tumor incidence [30]. These results suggest that *let-7b* or *let-7c* plays an important role in the intestinal tumorigenesis in mice.

4. *Let-7* Target mRNAs in Intestine

As *let-7* target mRNAs in the intestinal epithelium, Madison et al. revealed that *HMGA1*, *HMGA2*, *IGF2BP2*, *HIF3A*, *ARID3A*, and *E2F5* were the most highly induced targets of *let-7* microRNAs in the context of intestinal homeostasis [31]. Among these target molecules, the protein expression levels of *HMGA1*, *HMGA2*, *ARID3A*, and *HIF3A* were dramatically increased in the intestinal tumors. They also demonstrated that *HMGA2* plays an important role in the downstream of *let-7* in the context of colonic tumorigenesis. They found that the forced expression of *HMGA2* could increase the colony forming capacity in intestinal organoids and that the haploinsufficiency of *HMGA2* significantly decreased the tumor incidence in *villin-Lin28b* mice. *HMGA2* is a member of the High Mobility Group A class of proteins which bind to AT-rich DNA stretches and modulate gene expression by introducing structural alterations in the chromatin landscape [32]. *HMGA2*-deficiency impaired the growth in mice, whereas the transgenic expression of *HMGA2* variants enhanced the formation of benign tumors, indicating that *HMGA2* confers a growth advantage and thus promotes tumorigenesis [33]. In fact, overexpression of *HMGA2* was reported to promote metastasis and impact the survival of CRC patients [34]. RNA binding protein *IGF2BP1* (*IMP1*) is also considered as a *let-7* target molecule and highly expressed during developmental process, and prominent up-regulation and/or de novo synthesis are observed in various tumors [33, 35]. Hamilton et al. demonstrated that enforced expression of *IMP1* in SW480 cells could increase the growth of xenografts [36], which indicates that *IMP1* plays an important role in the formation or dissemination of colon cancer.

5. Functions of *Let-7* in the Colonic Tumorigenesis

5.1. Cell Cycle, Proliferation, and Apoptosis. The downregulation of *let-7* promotes cell proliferation through the activation of a variety of cellular proliferation signaling and cell cycle signaling pathways. For instance, *let-7* negatively regulates RAS expression through direct binding, which could down-regulate MAPK pathway and PI3K/AKT pathway [11, 37]. *Let-7* also directly downregulates some oncoproteins such as MYC, *HMGA2*, and *IGF1* [38–41] that are known as critical regulators for the growth of CRC.

The downregulation of *let-7* upregulates some cell cycle regulators such as cyclin A2, cyclin D1/2, CDK6, CDC34, CDC25A, Aurora A and B kinases, CDK8, *PLAGL2*, and *TRIM71*, which results in the activation of cell cycle [11, 42]. *Let-7* also inhibits cell proliferation by regulating transcriptional factors such as *STAT3*, *E2F5*, *E2F6*, *CBFB*, *PLAGL2*, *SOX9*, *GZF1*, *YAP1*, *GTF2I*, and *ARID3A* [42, 43]. *Let-7* microRNAs also suppress cell proliferation by regulating Wnt signaling. The inhibition of Wnt signaling by *let-7* is reported in various types of cancers [44–47]. In the context of intestinal tumorigenesis, Tu et al. demonstrated that overexpressed *LIN28* could accelerate the growth of intestinal tumors in *Apc^{Min/+}* mice and that this tumor-promoting effect was *let-7* dependent [28].

The relationship between *let-7* microRNAs and apoptosis in CRC is still controversial. Geng et al. reported that *let-7* inhibited apoptosis by decreasing the expression of *Fas* through the direct inhibition against *Fas* mRNA in HT29 cells [48]. They demonstrated that *let-7* inhibition increased *Fas* expression and the sensitivity to the FAS-related apoptosis. Conversely, Zhang et al. demonstrated that forced expression of *let-7c* promoted apoptosis in CRC cell lines at least by targeting *BCL2L1* [49]. Mongroo et al. showed that the loss of *IMP1*, a *let-7* target, promoted caspase- and lamin-mediated cell death through *CYFIP2* by the cross-talk with *KRAS* in SW480 cells [50]. Another *let-7* target in intestine, *HMGA2*, was reported to inhibit apoptosis [51]. The effect of *let-7* microRNAs on apoptosis might be context-dependent and so further investigation will be needed.

5.2. *Let-7* and Intestinal Stem Cells. Intestinal stem cell marker *LGR5* is known to be upregulated in human colon cancers and sporadic adenomas [67]. The intestinal stem cell markers such as *LGR5*, *ASCL2*, *SMOC2*, *Msi1*, and *Tert* are also known to be increased in colitis-associated carcinogenesis [68]. Madison et al. examined the expression levels of *let-7* microRNAs and intestinal stem cell markers (e.g., *LGR5*, *EPHB2*, and *ASCL2*) in human CRC tissues and normal adjacent tissues. *Let-7a* and *let-7b* were significantly downregulated in CRC specimens, while intestinal stem cell markers were significantly upregulated, which suggests that depletion of *let-7a* and *let-7b* may contribute to a stem cell phenotype in CRC [31]. They also demonstrated that tumors from *Villin-Lin28b/let-7^{IEC-KO}* mice exhibited a significant upregulation of stem cell markers including *Bmi1*, *Lgr1*, *Olfm4*, *ASCL2*, *Prom1*, *LGR5*, *Msi1*, and *SOX9*, suggesting an expansion of CRC and +4 stem cell-like compartments. They evaluated the coexpression of *let-7* target mRNAs and stem cell markers in mouse samples, and found that *HMGA1* and *HMGA2* were intensely correlated with stem cell markers. *HMGA2* expression was also correlated with *LGR5* expression in human CRC samples [31].

5.3. Tumor Progression and *Let-7* MicroRNAs in CRC. The downregulation of *let-7* promotes migration and invasion of normal intestinal epithelial cells and CRC cells [27]. Xenografts of the DLD-1 cells in which *let-7* expression was decreased by *LIN28B* overexpression developed lung and liver metastases in a mouse model, which suggests that *LIN28B/let-7* axis could affect the metastasis in CRC [26]. Some *let-7* target oncogenes such as *RAS* and *MYC* might contribute to the tumor progression [69, 70]. *HMGA2*, one of the *let-7* target molecules in intestine, is reported to promote epithelial-to-mesenchymal transition (EMT) through the induction of transcription factor *Slug* [71]. Forced expression of another *let-7* target *IMP1* in CRC cell line promoted the growth of xenograft tumors and dissemination into the blood in a mouse model. *IMP1* overexpression decreased the expression of E-cadherin, suggesting that *IMP1* contributes to the tumor progression through the loss of epithelial identity [36].

5.4. *Let-7* and Chemoresistance. The downregulation of *let-7* has been reported to contribute to the acquisition of

TABLE 1: MicroRNA replacement therapy with mimics.

microRNA	Cancer
microRNA-29	Lung [52]
microRNA-31	Neuroblastoma [53]
microRNA-34a	Neuroblastoma [54], Lung [55–57], HCC [58], Pancreas [59], Lymphoma [60], Prostate [61], Multiple Myeloma [62]
microRNA-113b	Lung [63]
microRNA-143	CRC [64], Pancreas [59]
microRNA-145	Pancreas [59], Lung [65]
microRNA-365	CRC [66]
<i>LET-7</i>	Lung [55]

CRC: colorectal cancer; HCC: hepatocellular carcinoma.

resistance against chemotherapy in many types of cancers such as breast cancer [72], esophageal cancer [43], acute myeloid leukemia [73], pancreatic cancer [74], ovarian cancer [75], and HCC [76]. Although only a single paper reported that the high *let-7g* expression was significantly associated with the chemoresistance against S-1 in CRC patients [77], most of the studies have shown that the downregulation of *let-7* contributes to the chemoresistance in the context of CRC. One of the underlying mechanisms by which the down-regulated *let-7* contributes to the chemoresistance is that the decreased *let-7* induces the expression of DNA excision repair protein, excision repair cross-complementing group 1 (ERCC1), which contributes to the resistance against cisplatin or 5-FU [25].

Let-7 microRNAs play an important role in regulating the response to antiepidermal growth factor receptor (EGFR) therapies in CRC patients. Cappuzzo et al. demonstrated that the KRAS wild-type metastatic CRC patients with high *let-7c* exhibited better response to EGFR monoclonal antibodies [78]. Although anti-EGFR treatment is not effective in CRC patients with mutated KRAS, Ruzzo et al. reported that the upregulation of *let-7a* may rescue the sensitivity of anti-EGFR therapies in such CRC patients [79]. A functional variant of a *let-7* complementary site (LCS6) in the KRAS 3' UTR mRNA might be a useful biomarker to predict the sensitivity of anti-EGFR therapies in patients with metastatic CRC, and further prospective confirmation is needed [80].

6. *Let-7* MicroRNAs as a Therapeutic Target

As discussed above, accumulating evidence has indicated that *let-7* microRNAs function as a tumor suppressor in CRC. Therefore, gene replacement therapy which attempts to introduce the analogous *let-7* molecules could be effective. Recent advances in genetic engineering have enabled us to make the microRNA mimics, artificial structures of RNA duplexes, that are identical to the mature microRNA sequence. An microRNA mimic is designed to have the function of the endogenous microRNA, attempting to restore its loss of function as a tumor suppressor [81]. However, systemic administration of microRNAs mimics might induce unexpected side effects because microRNAs including *let-7* can be functional not only in cancer cells but also in normal cells (i.e., development, cell proliferation, apoptosis, cell cycle control, differentiation, migration, and metabolism [82, 83]).

Therefore, alternative delivery systems functionalized with miRNA using nanoparticles have recently gained intense attention [53] and have been investigated *in vitro/in vivo* and also in clinical trials. Different types of microRNA mimics have been used in the medical field as therapeutic agents loaded on the surface of nanoparticles (Table 1). *Let-7* mimics have been proved to have therapeutic efficacy in mouse models of lung and prostate cancers [55, 84]. These delivery systems have been tested on several animal models, and some disadvantages regarding toxicity, immune, and inflammatory responses were observed [85].

For clinical application, gene replacement therapy with microRNA mimics met many obstacles: the instability of therapeutic molecules, nonspecific inflammation, controlled release of therapeutic molecules, specificity and efficiency of the delivery systems [53]. Advanced delivery strategies are still needed.

7. Conclusions

Accumulating evidence has showed that *let-7* microRNAs function as tumor suppressor through the posttranscriptional regulation of target mRNAs in CRC. *Let-7* microRNAs regulate various biological events such as cell proliferation, cell cycle, migration, progression, stem cell biology, metabolism, and chemoresistance. Gene replacement therapy with *let-7* mimics which attempts to restore the tumor suppressive function of *let-7* is tested and therapeutic efficacy has been proved in both *in vitro* experiments and *in vivo* animal models. However, many obstacles still remain to be overcome for the safe clinical application. Advanced drug delivery strategies are required.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding this paper.

References

- [1] M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, and E. Negri, "European cancer mortality predictions for the year 2014," *Annals of Oncology*, 2014.
- [2] M. Hori, T. Matsuda, A. Shibata, K. Katanoda, T. Sobue, and H. Nishimoto, "Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for

- the Monitoring of Cancer Incidence in Japan (MCIJ) project," *Japanese Journal of Clinical Oncology*, vol. 45, no. 9, pp. 884–891, 2015.
- [3] A. Jemal, E. M. Ward, C. J. Johnson et al., "Annual report to the nation on the status of cancer, 1975–2014, featuring survival," *Journal of the National Cancer Institute*, vol. 109, no. 9, Article ID dx030, 2017.
 - [4] M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, "Global patterns and trends in colorectal cancer incidence and mortality," *Gut*, vol. 66, no. 4, pp. 683–691, 2016.
 - [5] B. J. Reinhart, F. J. Slack, M. Basson et al., "The 21-nucleotide let-7 RNA regulates developmental timing in *Caenorhabditis elegans*," *Nature*, vol. 403, no. 6772, pp. 901–906, 2000.
 - [6] A. E. Rougvie, "Control of developmental timing in animals," *Nature Reviews Genetics*, vol. 2, no. 9, pp. 690–701, 2001.
 - [7] V. Ambros, "microRNAs: tiny regulators with great potential," *Cell*, vol. 107, no. 7, pp. 823–826, 2001.
 - [8] S. Roush and F. J. Slack, "The let-7 family of microRNAs," *Trends in Cell Biology*, vol. 18, no. 10, pp. 505–516, 2008.
 - [9] I. Berindan-Neagoe and G. A. Calin, "Molecular pathways: MicroRNAs, cancer cells, and microenvironment," *Clinical Cancer Research*, vol. 20, no. 24, pp. 6247–6253, 2014.
 - [10] S. R. Viswanathan and G. Q. Daley, "Lin28: A MicroRNA Regulator with a Macro Role," *Cell*, vol. 140, no. 4, pp. 445–449, 2010.
 - [11] T. Wang, G. Wang, D. Hao et al., "Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer," *Molecular Cancer*, vol. 14, no. 1, article no. 125, 2015.
 - [12] H. Lee, S. Han, C. S. Kwon, and D. Lee, "Biogenesis and regulation of the let-7 miRNAs and their functional implications," *Protein & Cell*, vol. 7, no. 2, pp. 100–113, 2016.
 - [13] E. Balzer and E. G. Moss, "Localization of the developmental timing regulator Lin28 to mRNP complexes, P-bodies and stress granules," *RNA Biology*, vol. 4, no. 1, pp. 16–25, 2007.
 - [14] M. A. Newman, J. M. Thomson, and S. M. Hammond, "Lin28 interaction with the Let-7 precursor loop mediates regulated microRNA processing," *RNA*, vol. 14, no. 8, pp. 1539–1549, 2008.
 - [15] E. Piskounova, C. Polytaichou, J. E. Thornton et al., "Lin28A and Lin28B inhibit let-7 MicroRNA biogenesis by distinct mechanisms," *Cell*, vol. 147, no. 5, pp. 1066–1079, 2011.
 - [16] F. Mayr and U. Heinemann, "Mechanisms of Lin28-mediated miRNA and mRNA regulation—a structural and functional perspective," *International Journal of Molecular Sciences*, vol. 14, no. 8, pp. 16532–16553, 2013.
 - [17] Y. Nam, C. Chen, R. I. Gregory, J. J. Chou, and P. Sliz, "Molecular basis for interaction of let-7 microRNAs with Lin28," *Cell*, vol. 147, no. 5, pp. 1080–1091, 2011.
 - [18] F. E. Loughlin, L. F. R. Gebert, H. Towbin, A. Brunschweiler, J. Hall, and F. H.-T. Allain, "Structural basis of pre-let-7 miRNA recognition by the zinc knuckles of pluripotency factor Lin28," *Nature Structural & Molecular Biology*, vol. 19, no. 1, pp. 84–91, 2012.
 - [19] E. Piskounova, S. R. Viswanathan, M. Janas et al., "Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28," *The Journal of Biological Chemistry*, vol. 283, no. 31, pp. 21310–21314, 2008.
 - [20] J. P. Hagan, E. Piskounova, and R. I. Gregory, "Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells," *Nature Structural & Molecular Biology*, vol. 16, no. 10, pp. 1021–1025, 2009.
 - [21] I. Heo, C. Joo, J. Cho, M. Ha, J. Han, and V. N. Kim, "Lin28 mediates the terminal uridylation of let-7 precursor microRNA," *Molecular Cell*, vol. 32, no. 2, pp. 276–284, 2008.
 - [22] I. Heo, C. Joo, Y.-K. Kim et al., "TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation," *Cell*, vol. 138, no. 4, pp. 696–708, 2009.
 - [23] T. E. Mullen and W. F. Marzluff, "Degradation of histone mRNA requires oligouridylation followed by decapping and simultaneous degradation of the mRNA both 5' to 3' and 3' to 5'," *Genes & Development*, vol. 22, no. 1, pp. 50–65, 2008.
 - [24] H.-M. Chang, R. Triboulet, J. E. Thornton, and R. I. Gregory, "A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway," *Nature*, vol. 497, no. 7448, pp. 244–248, 2013.
 - [25] R. Mizuno, P. Chatterji, and S. Andres, "Differential Regulation of LET-7 by LIN28B Isoform-Specific Functions," *Mol Cancer Res*, vol. 16, no. 3, pp. 403–416, 2018.
 - [26] C. E. King, M. Cuatrecasas, A. Castells, A. R. Sepulveda, J.-S. Lee, and A. K. Rustgi, "LIN28B promotes colon cancer progression and metastasis," *Cancer Research*, vol. 71, no. 12, pp. 4260–4268, 2011.
 - [27] C. E. King, L. Wang, R. Winograd et al., "LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and-independent mechanisms," *Oncogene*, vol. 30, no. 40, pp. 4185–4193, 2011.
 - [28] H.-C. Tu, S. Schwitala, Z. Qian et al., "LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans," *Genes & Development*, vol. 29, no. 10, pp. 1074–1086, 2015.
 - [29] B. B. Madison, Q. Liu, X. Zhong et al., "LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7," *Genes & Development*, vol. 27, no. 20, pp. 2233–2245, 2013.
 - [30] R. Triboulet, M. Pirouz, and R. I. Gregory, "A Single Let-7 MicroRNA Bypasses LIN28-Mediated Repression," *Cell Reports*, vol. 13, no. 2, pp. 260–266, 2015.
 - [31] B. B. Madison, A. N. Jeganathan, R. Mizuno et al., "Let-7 represses carcinogenesis and a stem cell phenotype in the intestine via regulation of Hmga2," *PLoS Genetics*, vol. 11, no. 8, Article ID e1005408, 2015.
 - [32] S. L. Yong and A. Dutta, "The tumor suppressor microRNA let-7 represses the HMGA2 oncogene," *Genes & Development*, vol. 21, no. 9, pp. 1025–1030, 2007.
 - [33] B. Busch, N. Bley, S. Müller et al., "The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family," *Nucleic Acids Research*, vol. 44, no. 8, pp. 3845–3864, 2016.
 - [34] X. Wang, X. Liu, A. Y.-J. Li et al., "Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers," *Clinical Cancer Research*, vol. 17, no. 8, pp. 2570–2580, 2011.
 - [35] J. L. Bell, K. Wächter, B. Mühleck et al., "Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of cancer progression?" *Cellular and Molecular Life Sciences*, vol. 70, no. 15, pp. 2657–2675, 2013.
 - [36] K. E. Hamilton, F. K. Noubissi, P. S. Katti et al., "IMP1 promotes tumor growth, dissemination and a tumor-initiating cell phenotype in colorectal cancer cell xenografts," *Carcinogenesis*, vol. 34, no. 11, pp. 2647–2654, 2013.
 - [37] S. M. Johnson, H. Grosshans, J. Shingara et al., "RAS is regulated by the let-7 microRNA family," *Cell*, vol. 120, no. 5, pp. 635–647, 2005.
 - [38] H. J. Jung and Y. Suh, "Regulation of IGF -1 signaling by microRNAs," *Frontiers in Genetics*, vol. 5, no. 472, 2014.

- [39] K. Zhang, H. Gao, X. Wu et al., "Frequent overexpression of HMGA2 in human atypical teratoid/rhabdoid tumor and its correlation with let-7a3/let-7b miRNA," *Clinical Cancer Research*, vol. 20, no. 5, pp. 1179–1189, 2014.
- [40] K.-J. Chen, Y. Hou, K. Wang et al., "Reexpression of let-7g microRNA inhibits the proliferation and migration via K-Ras/HMGA2/snail axis in hepatocellular carcinoma," *BioMed Research International*, vol. 2014, Article ID 742417, 2014.
- [41] J. Balzeau, M. R. Menezes, S. Cao, and J. P. Hagan, "The LIN28/let-7 pathway in cancer," *Frontiers in Genetics*, vol. 8, no. 31, 2017.
- [42] D. Barh, R. Malhotra, B. Ravi, and P. Sindhurani, "MicroRNA let-7: an emerging next-generation cancer therapeutic," *Current Oncology*, vol. 17, no. 1, pp. 70–80, 2010.
- [43] K. Sugimura, H. Miyata, K. Tanaka et al., "Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma," *Clinical Cancer Research*, vol. 18, no. 18, pp. 5144–5153, 2012.
- [44] B. Jin, W. Wang, X.-X. Meng et al., "Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway," *BMC Cancer*, vol. 16, no. 1, article no. 863, 2016.
- [45] H. Cai, Y. Chen, X. Yang et al., "Let7b modulates the Wnt/ β -catenin pathway in liver cancer cells via downregulated Frizzled4," *Tumor Biology*, vol. 39, no. 7, pp. 1–7, 2017.
- [46] X. Sun, C. Xu, S.-C. Tang et al., "Let-7c blocks estrogen-activated Wnt signaling in induction of self-renewal of breast cancer stem cells," *Cancer Gene Therapy*, vol. 23, no. 4, pp. 83–89, 2016.
- [47] J. L. Viñas, M. Ventayol, B. Brüne et al., "miRNA let-7e modulates the wnt pathway and early nephrogenic markers in mouse embryonic stem cell differentiation," *PLoS ONE*, vol. 8, no. 4, Article ID e60937, 2013.
- [48] L. Geng, B. Zhu, B.-H. Dai et al., "A let-7/Fas double-negative feedback loop regulates human colon carcinoma cells sensitivity to Fas-related apoptosis," *Biochemical and Biophysical Research Communications*, vol. 408, no. 3, pp. 494–499, 2011.
- [49] H. Zhang, Y. Zong, G. Qiu et al., "Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let7c targeting of antiapoptotic BCL2L1," *Molecular Medicine Reports*, vol. 17, no. 4, pp. 5143–5149, 2018.
- [50] P. S. Mongroo, F. K. Noubissi, M. Cuatrecasas et al., "IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2," *Cancer Research*, vol. 71, no. 6, pp. 2172–2182, 2011.
- [51] A. W. Nana, Y. Chin, C. Lin et al., "Tetrac downregulates β -catenin and HMGA2 to promote the effect of resveratrol in colon cancer," *Endocrine-Related Cancer*, vol. 25, no. 3, pp. 279–293, 2018.
- [52] Y. Wu, M. Crawford, Y. Mao et al., "Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer," *Molecular Therapy—Nucleic Acids*, vol. 2, article e84, 2013.
- [53] A. Jurj, C. Braicu, L.-A. Pop, C. Tomuleasa, C. D. Gherman, and I. Berindan-Neagoe, "The new era of nanotechnology, an alternative to change cancer treatment," *Drug Design, Development and Therapy*, vol. 11, pp. 2871–2890, 2017.
- [54] A. Tivnan, W. S. Orr, V. Gubala et al., "Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles," *PLoS ONE*, vol. 7, no. 5, Article ID e38129, 2012.
- [55] P. Trang, J. F. Wiggins, C. L. Daige et al., "Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice," *Molecular Therapy*, vol. 19, no. 6, pp. 1116–1122, 2011.
- [56] Q. L. Hu, Q. Y. Jiang, X. Jin et al., "Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model," *Biomaterials*, vol. 34, no. 9, pp. 2265–2276, 2013.
- [57] J. F. Wiggins, L. Ruffino, K. Kelnar et al., "Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34," *Cancer Research*, vol. 70, no. 14, pp. 5923–5930, 2010.
- [58] A. G. Bader, "MiR-34 - a microRNA replacement therapy is headed to the clinic," *Frontiers in Genetics*, vol. 3, article 120, 2012.
- [59] D. Pramanik, N. R. Campbell, C. Karikari et al., "Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice," *Molecular Cancer Therapeutics*, vol. 10, no. 8, pp. 1470–1480, 2011.
- [60] V. J. Craig, A. Tzankov, M. Flori, C. A. Schmid, A. G. BaDer, and A. Müller, "Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo," *Leukemia*, vol. 26, no. 11, pp. 2421–2424, 2012.
- [61] C. Liu, K. Kelnar, B. Liu et al., "The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44," *Nature Medicine*, vol. 17, no. 2, pp. 211–215, 2011.
- [62] D. Cosco, F. Cilurzo, J. Maiuolo et al., "Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma," *Scientific Reports*, vol. 5, Article ID 17579, 2015.
- [63] Y. Wu, M. Crawford, B. Yu, Y. Mao, S. P. Nana-Sinkam, and L. J. Lee, "MicroRNA delivery by cationic lipoplexes for lung cancer therapy," *Molecular Pharmaceutics*, vol. 8, no. 4, pp. 1381–1389, 2011.
- [64] P. M. Borralho, B. T. Kren, R. E. Castro, I. B. Moreira da Silva, C. J. Steer, and C. M. P. Rodrigues, "MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells," *FEBS Journal*, vol. 276, no. 22, pp. 6689–6700, 2009.
- [65] G.-Y. Chiou, J.-Y. Cherng, H.-S. Hsu et al., "Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma," *Journal of Controlled Release*, vol. 159, no. 2, pp. 240–250, 2012.
- [66] J. Nie, L. Liu, W. Zheng et al., "microRNA-365, down-regulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2," *Carcinogenesis*, vol. 33, no. 1, pp. 220–225, 2012.
- [67] H. Uchida, K. Yamazaki, M. Fukuma et al., "Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer," *Cancer Science*, vol. 101, no. 7, pp. 1731–1737, 2010.
- [68] H. S. Kim, C. Lee, W. H. Kim, Y. H. Maeng, and B. G. Jang, "Expression profile of intestinal stem cell markers in colitis-associated carcinogenesis," *Scientific Reports*, vol. 7, no. 1, 2017.
- [69] S. Goel, J. Huang, and L. Klampfer, "K-Ras, Intestinal homeostasis and colon cancer," *Current Clinical Pharmacology*, vol. 10, no. 1, pp. 73–81, 2015.
- [70] S. J. Garte, "The c-myc oncogene in tumor progression," *Critical Reviews in Oncogenesis*, vol. 4, no. 4, pp. 435–449, 1993.
- [71] Y. Li, Z. Zhao, C. Xu, Z. Zhou, Z. Zhu, and T. You, "HMGA2 induces transcription factor Slug expression to promote epithelial-to-mesenchymal transition and contributes to

- colon cancer progression," *Cancer Letters*, vol. 355, no. 1, pp. 130–140, 2014.
- [72] K. Lv, L. Liu, L. Wang et al., "Lin28 mediates paclitaxel resistance by modulating p21, Rb and Let-7a miRNA in breast cancer cells," *PLoS ONE*, vol. 7, no. 7, Article ID e40008, 2012.
 - [73] Y. Chen, R. Jacamo, M. Konopleva, R. Garzon, C. Croce, and M. Andreeff, "CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia," *The Journal of Clinical Investigation*, vol. 123, no. 6, pp. 2395–2407, 2013.
 - [74] Y. D. Bhutia, S. W. Hung, M. Krentz et al., "Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein," *PLoS ONE*, vol. 8, no. 1, Article ID e53436, 2013.
 - [75] H. Zhu, S.-C. Ng, A. V. Segrè et al., "The Lin28/let-7 axis regulates glucose metabolism," *Cell*, vol. 147, no. 1, pp. 81–94, 2011.
 - [76] X. Ma, C. Li, L. Sun et al., "Lin28/let-7 axis regulates aerobic glycolysis and cancer progression via PDK1," *Nature Communications*, vol. 5, article no. 5212, 2014.
 - [77] G. Nakajima, K. Hayashi, Y. Xi et al., "Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer," *Cancer Genomics & Proteomics*, vol. 3, no. 5, pp. 317–324, 2006.
 - [78] F. Cappuzzo, A. Sacconi, L. Landi et al., "MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies," *Clinical Colorectal Cancer*, vol. 13, no. 1, pp. 37–45.e4, 2014.
 - [79] A. Ruzzo, F. Graziano, B. Vincenzi et al., "High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease," *The Oncologist*, vol. 17, no. 6, pp. 823–829, 2012.
 - [80] Z. Saridaki, J. B. Weidhaas, H.-J. Lenz et al., "A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy," *Clinical cancer research : an official journal of the American Association for Cancer Research*, vol. 20, no. 17, pp. 4499–4510, 2014.
 - [81] C. Braicu, C. Tomuleasa, P. Monroig, A. Cucuianu, I. Berindan-Neagoe, and G. A. Calin, "Exosomes as divine messengers: are they the Hermes of modern molecular oncology?" *Cell Death & Differentiation*, vol. 22, no. 1, pp. 34–45, 2015.
 - [82] M. D. Jansson and A. H. Lund, "MicroRNA and cancer," *Molecular Oncology*, vol. 6, no. 6, pp. 590–610, 2012.
 - [83] A. Ekin, O. F. Karatas, M. Culha, and M. Ozen, "Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells," *The Journal of Gene Medicine*, vol. 16, no. 11-12, pp. 331–335, 2014.
 - [84] P. Hydbring and G. Badalian-Very, "Clinical applications of microRNAs," *F1000Research*, vol. 2, article 136, 2013.
 - [85] W. Guo, W. Chen, W. Yu, W. Huang, and W. Deng, "Small interfering RNA-based molecular therapy of cancers," *Chinese Journal of Cancer*, vol. 32, no. 9, pp. 488–493, 2013.